ClinicalTrials.gg
CompletedNCT07036419Updated Jun 4, 2026

A Trial of Remimazolam for Intraoperative Sedation in Pediatric and Adolescent Patients

A Phase 2/3 interventional study of Remimazolam Tosilate for injection and Propofol Injection in Operative Sedation of Pediatric and Operative Sedation of Adolescent Patients, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 3 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-06-04.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
249
Allocation
Randomized
Ages
3 Years to 17 Years
Sex
All
01

Study summary

The study is being conducted to evaluate the efficacy and safety of Remimazolam for intraoperative sedation in pediatric and adolescent patients.

02

Conditions studied

  • Operative Sedation of Pediatric
  • Operative Sedation of Adolescent Patients
03

In context

Lead sponsor

Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able and willing to provide a written .
  2. Subjects requiring elective general anesthesia surgery.
  3. Male or female.
  4. Meet the weight standard.

Exclusion criteria

Exclusion Criteria:

  1. Pediatric patients scheduled for elective cardiothoracic, neurosurgical, or hepatic surgery.
  2. Patients who are planned to receive any anesthetic techniques other than total intravenous anesthesia (TIVA) from entry into the operating room until the end of surgery, such as inhalational anesthesia, epidural anesthesia, or spinal anesthesia.
  3. Patients with a medical history or clinical evidence that may increase the risk of sedation or anesthesia and are deemed unsuitable for participation by the investigator.
  4. Patients with a history of asthma or with risk for difficult mask ventilation or difficult intubation by the investigator's judgment.
  5. With abnormal clinical laboratory test value.
  6. Known intolerance or allergy to benzodiazepines, propofol, opioids, neuromuscular blocking agents, or any of their components.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
249 participants (actual)

Study arms

  • Experimental
    Remimazolam Group

    Drug: Remimazolam Tosilate for injection

  • Active comparator
    Propofol Group

    Drug: Propofol Injection

Interventions

06

What researchers measure

Primary outcomes

  1. The overall sedation success rate.

    The overall sedation success rate, which encompasses both successful induction of sedation and successful maintenance of adequate sedation throughout the anesthesia procedure.

    Time frame: Throughout the anesthesia procedure.

Secondary outcomes

  1. Proportion of subjects with hemodynamic instability.

    Defined as a ≥ ±20% change from the baseline in blood pressure or heart rate.

    Time frame: Up to 2 days.

  2. Incidence and severity of adverse events during the study.

    Time frame: Up to 3 days.

07

Study locations

1 site
  • Shanghai Children's Medical Center Affiliated to Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai Municipality 200433, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2025 to primary completion in May 2026, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2025
First posted
Jun 25, 2025
StartActual
Jul 10, 2025
Primary completionActual
May 27, 2026
CompletionActual
May 27, 2026
Last update
Jun 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07036419
Responsible party
Sponsor
First posted
Jun 25, 2025
Start date
Jul 10, 2025
Primary completion
May 27, 2026
Completion
May 27, 2026
Last update
Jun 4, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Remimazolam tosylate

Start the discussion